Literature DB >> 6641763

Abnormal fatty acid pattern of the plasma cholesterol ester fraction in cystic fibrosis patients with and without pancreatic insufficiency.

V Rogiers, A Vercruysse, I Dab, D Baran.   

Abstract

In our previous work it was found that in cystic fibrosis patients with and without pancreatic insufficiency, the fatty acid pattern of the plasma long chain, non-esterified fatty acid fraction is strikingly abnormal in comparison with the corresponding pattern of healthy subjects. However, other investigators have shown abnormal fatty acid patterns only in patients with pancreatic insufficiency. Therefore, we studied the plasma cholesterol ester fraction in cystic fibrosis patients of both types by gas liquid chromatography. It was found that the absolute total concentration of the plasma cholesterol esters in cystic fibrosis patients with and also without pancreatic insufficiency is significantly lower than in healthy subjects. Furthermore, the fatty acid pattern of this lipid fraction is significantly abnormal in both groups of patients, although to a lesser extent in patients without pancreatic insufficiency.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641763     DOI: 10.1007/BF00445666

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  23 in total

1.  Cystic fibrosis of the pancreas: intestinal absorption of fat and fatty acid labeled with I 131.

Authors:  K REEMTSMA; P A DI SANT'AGNESE; J R MALM; H G BARKER
Journal:  Pediatrics       Date:  1958-09       Impact factor: 7.124

2.  A therapeutic trial of fatty acid supplementation in cystic fibrosis.

Authors:  R B Elliott
Journal:  Pediatrics       Date:  1976-04       Impact factor: 7.124

3.  Efficiency of two pancreatic extracts in patients with cystic fibrosis.

Authors:  D Baran; H Loeb; M J Mozin
Journal:  Acta Paediatr Belg       Date:  1976 Apr-Jun

4.  Intravenous linoleic acid supplementation in children with cystic fibrosis.

Authors:  H P Chase; E K Cotton; R B Elliott
Journal:  Pediatrics       Date:  1979-08       Impact factor: 7.124

5.  Essential fatty acids in cystic fibrosis.

Authors:  M L Rosenlund; H K Kim; D Kritchevsky
Journal:  Nature       Date:  1974-10-25       Impact factor: 49.962

6.  The effect of medium chain triglyceride upon fat absorption and plasma lipid and depot fat of children with cystic fibrosis of the pancreas.

Authors:  P T Kuo; N N Huang
Journal:  J Clin Invest       Date:  1965-11       Impact factor: 14.808

7.  Plasma fatty acids in pancreatic cystic fibrosis and liver disease.

Authors:  R Caren; L Corbo
Journal:  J Clin Endocrinol Metab       Date:  1966-04       Impact factor: 5.958

8.  Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents.

Authors:  V Rogiers; I Dab; R Crokaert; H L Vis
Journal:  Pediatr Res       Date:  1980-09       Impact factor: 3.756

9.  Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation.

Authors:  J D Lloyd-Still; S B Johnson; R T Holman
Journal:  Am J Clin Nutr       Date:  1981-01       Impact factor: 7.045

10.  Gas chromatographic determination of the fatty acid pattern of red cell membrane plasmalogens in healthy children.

Authors:  V Rogiers
Journal:  J Chromatogr       Date:  1980-04-11
View more
  14 in total

1.  Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect.

Authors:  J Carlstedt-Duke; M Brönnegård; B Strandvik
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 2.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

3.  What is the association of essential fatty acid status with cystic fibrosis?

Authors:  V S Hubbard
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

4.  Fatty acid pattern of platelet phospholipids in cystic fibrosis.

Authors:  V Rogiers; A Vercruysse; I Dab; R Crokaert; H L Vis
Journal:  Eur J Pediatr       Date:  1984-09       Impact factor: 3.183

5.  Prospective study of mycobacterial infections in patients with cystic fibrosis.

Authors:  L Hjelte; B Petrini; G Källenius; B Strandvik
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

6.  Pulmonary Tuberculosis in a Patient with Cystic Fibrosis.

Authors:  Naveen Patil; Asween Marco; Maria Theresa Montales; Nutan Bhaskar; Penchala Mittadodla; Leonard N Mukasa
Journal:  N Am J Med Sci       Date:  2015-05

7.  Absorption of safflower oil and structured lipid preparations in patients with cystic fibrosis.

Authors:  V S Hubbard; M C McKenna
Journal:  Lipids       Date:  1987-06       Impact factor: 1.880

8.  The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells.

Authors:  J X Kang; S F Man; N E Brown; P A Labrecque; M T Clandinin
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

9.  A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA.

Authors:  M Rabie Al-Turkmani; Charlotte Andersson; Ragheed Alturkmani; Waddah Katrangi; Joanne E Cluette-Brown; Steven D Freedman; Michael Laposata
Journal:  J Lipid Res       Date:  2008-05-14       Impact factor: 5.922

10.  A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients.

Authors:  Ida Chiara Guerrera; Giuseppe Astarita; Jean-Philippe Jais; Dorota Sands; Anna Nowakowska; Julien Colas; Isabelle Sermet-Gaudelus; Martin Schuerenberg; Daniele Piomelli; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.